Development of T-cell receptors (TCR) for the adoptive T-cell therapy (ACT) of epithelial ovarian cancer (EOC)

PRINCIPLE INVESTIGATORS:
Prof. Dr. med. Sebastian Ochsenreither
Charité

SUMMARY
EOC is the most common cause of death of gynecological malignancies. Due to its early peritoneal spread, patients are diagnosed in a metastatic setting in the majority of cases. Even though well responsible to cytostatic agents, patients eventually succumb to the disease, mostly after several lines of chemotherapy.

Our vision is develop new TCR constructs for ACT for potential treatment of EOC.

PROJECT GOALS
• Generation of novel TCR constructs for further development towards clinical application

LONG-TERM GOALS
• Clinical trial
• Licensing to industry